# Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Source: https://onco.cc/trials/nct02744287/  
OnCo record `nct02744287` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BPX-601 run by Regeneron Pharmaceuticals, terminated.

## Summary

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors is a phase 1 interventional study registered as NCT02744287 by Regeneron Pharmaceuticals, with 52 participants enrolled, started 2016-11-30. Conditions recorded: Metastatic Castration-resistant Prostate Cancer and Metastatic Prostate Cancer. Interventions recorded: BPX-601 and Rimiducid.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02744287
- Phase: 1
- Setting: A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT02744287: https://clinicaltrials.gov/study/NCT02744287

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [BPX-601](https://onco.cc/drugs/bpx-601/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/), [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct02744287.json